Hospital-Acquired Pneumonia Diagnosis and Treatment

Definition and Diagnosis

• Hospital-acquired pneumonia (HAP) is defined as pneumonia occurring ≥48 hours after hospitalization in non-intubated patients, and should be diagnosed based on clinical criteria including new or progressive radiographic infiltrates plus clinical signs (fever, leukocytosis, purulent secretions) rather than biomarkers alone 1, 2

Risk Stratification for Empiric Therapy

• For patients with early-onset HAP (<5 days hospitalization) and no risk factors for multidrug-resistant (MDR) pathogens, the American College of Physicians recommends using narrow-spectrum monotherapy 2
• Broad-spectrum empiric therapy targeting MRSA, Pseudomonas aeruginosa, and other gram-negative bacilli is mandatory for patients with any of the following risk factors: prior intravenous antibiotic use within 90 days, hospitalization in a unit where >20% of S. aureus isolates are methicillin-resistant (MRSA) or MRSA prevalence is unknown, septic shock or need for ventilatory support due to HAP, hospitalization >5 days, structural lung disease (bronchiectasis, cystic fibrosis), or prior colonization with MDR pathogens 1, 3, 2

Empiric Antibiotic Regimens

• The Infectious Diseases Society of America recommends that empiric therapy must include coverage for Pseudomonas aeruginosa and other gram-negative bacilli using an antipseudomonal beta-lactam 3, 4, 2
• For patients with factors increasing likelihood of Pseudomonas infection (prior IV antibiotics within 90 days, structural lung disease) or high mortality risk (septic shock, ventilatory support), the American Thoracic Society recommends using combination therapy with two different antibiotic classes active against Pseudomonas 3, 4

Pharmacokinetic/Pharmacodynamic Optimization

• Antibiotic dosing should be determined using PK/PD data rather than standard manufacturer's prescribing information, as recommended by the American College of Clinical Pharmacy 1, 3, 4

Definitive Therapy Based on Culture Results

• For HAP/VAP due to P. aeruginosa, base definitive therapy on antimicrobial susceptibility testing results, as recommended by the Infectious Diseases Society of America 1
• For proven MRSA HAP/VAP, treat with either vancomycin or linezolid rather than other antibiotics, as recommended by the American College of Physicians 1, 4

De-escalation and Duration of Therapy

• The recommended duration for HAP treatment is 7-14 days, with shorter courses (7-8 days) appropriate for patients with uncomplicated HAP who received initially appropriate therapy and had a good clinical response, as recommended by the American Journal of Respiratory and Critical Care Medicine 5, 2
• De-escalate therapy based on culture results and clinical response, typically by day 3, as recommended by the Infectious Diseases Society of America 2, 6

Empiric Antibiotic Regimen for HAP with Prior Pseudomonas and Recent Cefepime Exposure

Introduction to Empiric Antibiotic Regimen

• The Infectious Diseases Society of America recommends using dual antipseudomonal coverage with an antipseudomonal beta-lactam from a different class, PLUS either an aminoglycoside or fluoroquinolone, combined with vancomycin or linezolid for MRSA coverage in patients with prior Pseudomonas infection treated with cefepime within the last month, worsening clinical picture, and high risk for multidrug-resistant organisms 7

Risk Stratification

• Prior IV antibiotic use within 90 days is a critical risk factor for both MDR gram-negatives and MRSA, according to the Infectious Diseases Society of America guidelines 7
• Tracheostomy represents structural airway alteration increasing risk for gram-negative pathogens, as stated by the Infectious Diseases Society of America 7
• Prior Pseudomonas colonization/infection significantly increases risk of recurrent resistant Pseudomonas, as noted by the Infectious Diseases Society of America 7

Recommended Empiric Regimen

• The Infectious Diseases Society of America recommends piperacillin-tazobactam 4.5g IV every 6 hours, PLUS tobramycin or amikacin, as a preferred option for dual antipseudomonal coverage 7
• The Infectious Diseases Society of America also recommends ceftazidime 2g IV every 8 hours, PLUS ciprofloxacin 400mg IV every 8 hours, as an alternative option for dual antipseudomonal coverage 7
• The Infectious Diseases Society of America suggests meropenem 1-2g IV every 8 hours, PLUS tobramycin or amikacin, as another option for dual antipseudomonal coverage 7
• Vancomycin 15-20 mg/kg IV every 8-12 hours, or linezolid 600mg IV every 12 hours, is recommended by the Infectious Diseases Society of America for MRSA coverage 7

Rationale for Dual Antipseudomonal Therapy

• The Infectious Diseases Society of America states that prior IV antibiotic use within 90 days is an explicit indication for dual coverage 7
• The Infectious Diseases Society of America notes that tracheostomy represents structural lung disease, another indication for dual therapy 7
• The Infectious Diseases Society of America recommends against using aminoglycosides as the sole antipseudomonal agent 7

Critical Pitfalls to Avoid

• The Infectious Diseases Society of America advises against using monotherapy in high-risk patients, as it is associated with treatment failure and resistance emergence 7
• The Infectious Diseases Society of America recommends against omitting MRSA coverage given prior antibiotic exposure 7
• The Infectious Diseases Society of America warns against using aminoglycoside alone for Pseudomonas, and recommends combining it with a beta-lactam 7

Hospital‑Acquired Pneumonia: Diagnostic and Therapeutic Guidelines

Diagnostic Criteria

• Hospital‑acquired pneumonia (HAP) is defined as pneumonia that arises ≥48 hours after hospital admission in patients who are not mechanically ventilated, requiring new or progressive infiltrates on chest imaging together with fever > 38.3 °C, abnormal white‑blood‑cell count, and/or purulent respiratory secretions. 8

• Radiological requirement – either two consecutive chest radiographs showing new or worsening infiltrates, or a single radiograph when underlying cardiac or pulmonary disease is absent. 8

• Core clinical signs – at least one of:

  • Body temperature > 38.3 °C without another identifiable cause,
  • White‑blood‑cell count < 4 × 10⁹/L or > 12 × 10⁹/L.
  • (Both criteria are supported by the same guideline.) 8

• Additional clinical features – at least two of the following are required:

  • Purulent sputum,
  • Cough or dyspnea,
  • Worsening oxygenation, increased oxygen need, or requirement for respiratory assistance. 8

• Temporal classification –

  • Early‑onset HAP: occurs < 5 days after admission; most often caused by methicillin‑susceptible Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae.
  • Late‑onset HAP: occurs ≥ 5 days after admission; more frequently associated with multidrug‑resistant (MDR) organisms. 8

• Microbiological yield – lower‑respiratory‑tract sampling before antibiotics identifies a causative pathogen in ≈ 70 % of suspected HAP cases. The most common isolates are Pseudomonas aeruginosa, Staphylococcus aureus (including MRSA), Enterobacteriaceae, and Acinetobacter baumannii; polymicrobial infection occurs in about 30 % of cases. 8

Empiric Antibiotic Selection

• The choice of empiric therapy is driven by three risk domains: mortality risk, MRSA risk, and MDR‑pathogen risk. 9

Low Mortality Risk, No MRSA Risk

• Monotherapy with an antipseudomonal β‑lactam (e.g., piperacillin‑tazobactam, cefepime, meropenem, or imipenem) is recommended; levofloxacin may be used as an alternative. 9

Low Mortality Risk, MRSA Risk Present

• Add MRSA coverage (vancomycin or linezolid) to the antipseudomonal β‑lactam regimen.
• MRSA risk factors include admission to a unit where > 20 % of S. aureus isolates are methicillin‑resistant or where MRSA prevalence is unknown. 9

High Mortality Risk or Recent IV Antibiotic Exposure (≤ 90 days)

• Dual antipseudomonal coverage plus MRSA coverage is advised. Example dual combinations:
  
  • Piperacillin‑tazobactam + an aminoglycoside (tobramycin or amikacin)
  • Ceftazidime + ciprofloxacin
  • Meropenem + an aminoglycoside.
• MRSA agents (vancomycin or linezolid) are added to the dual regimen.
• High‑mortality indicators include septic shock, need for ventilatory support due to HAP, hospital stay > 5 days, structural lung disease (e.g., bronchiectasis, cystic fibrosis), or prior colonisation with MDR organisms. 9

Early‑Onset HAP Without Additional Risk Factors

• For patients with early‑onset HAP (< 5 days), no septic shock, no recent antibiotics, and institutional MDR prevalence < 25 %, narrow‑spectrum agents are appropriate: amoxicillin‑clavulanate or cefuroxime, or alternatively ceftriaxone, cefotaxime, or moxifloxacin. 9

Critical Implementation Pitfalls

• Aminoglycosides must never be used alone as the sole antipseudomonal agent; they should always be combined with a β‑lactam. 9
• Monotherapy is contraindicated in high‑risk patients (recent antibiotic exposure, high mortality risk) because it increases treatment failure and resistance.
• Omitting MRSA coverage in settings with high MRSA prevalence or in patients with relevant risk factors leads to poorer outcomes.
• Delaying the first dose of antibiotics is associated with increased mortality; prompt initiation is essential. 9

Definitive Therapy, De‑escalation, and Duration

• Culture‑directed adjustment of the regimen should occur by day 3 based on microbiology results and clinical response.
• For uncomplicated HAP with a favourable response, a 7–8‑day total course is recommended rather than prolonged therapy.
• When a specific pathogen is identified:
  
  • Pseudomonas aeruginosa – tailor therapy to susceptibility results.
  • Proven MRSA – continue vancomycin or linezolid.
• De‑escalation from combination therapy to a single, targeted agent is encouraged whenever cultures permit, except for infections caused by extensively drug‑resistant organisms. 9